News & Updates

A substudy of the phase III FLAIR study has found comparable efficacy and pharmacokinetics for cabotegravir (CAB) plus rilpivirine (RPV) via subcutaneous (SC) administration relative to those via intramuscular (IM) gluteal injections among virally suppressed individuals living with HIV-1.

Certain individuals initially testing negative for tuberculosis (TB) by interferon-gamma release assay (IGRA) may later contract the infection and therefore require extended follow-up due to increased risk, as reported in a study from Singapore.

In COVID-19 patients who had mild or no symptoms, the use of 0.05% cetylpyridinium chloride (CPC) and 0.01% on-demand aqueous chlorine dioxide (ACD) mouthwashes did not lead to a reduction in SARS-CoV-2 salivary viral load.

Children with influenza A virus infection are susceptible to acute benign myositis (ABM), with most patients showing clinical characteristics consistent with postfebrile myalgia, reports a study.

Evaluation and treatment rates of patients with chronic hepatitis B (CHB) remain poor worldwide and differ by sex and race or ethnicity, reports a real-world study.

In a retrospective observational study, nirmatrelvir-ritonavir trumps molnupiravir in reducing the risk of all-cause mortality at 90 days and hospitalization in COVID-19 patients with advanced kidney disease (chronic kidney disease [CKD] stage 4, ie, eGFR <30 mL/min/1.73 m2).